Arcus Biosciences, Inc.
NYSE:RCUSBiotechnology
-$0.09 today
- Market cap
- $2.27B
- Beta
- 0.84
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$2.94
Volume 1.97M
Average 1.17M
RCUS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Arcus Biosciences, Inc.NYSE: RCUS
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development dips below year-ago levels
Q2 FY2026 research & development of $113M fell 18.7% year over year, behind the +2.5% change in trailing-twelve-month research & development. Sequentially, it fell 7.4% from the prior quarter. Over 3 fiscal years it compounded at +22.0% a year.
Context
- Research & development amounted to 211.7% of revenue in FY2025, up 38.1 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -18.7% toward the trailing-twelve-month pace of +2.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 523M USD
- Year-over-year change
- +16.7%
- 4-year CAGR
- +19.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 523M | +16.7% |
| FY2024 | 2024-12-31 | 448M | +31.8% |
| FY2023 | 2023-12-31 | 340M | +18.1% |
| FY2022 | 2022-12-31 | 288M | +12.1% |
| FY2021 | 2021-12-31 | 257M | — |
Research & Development vs competitors
How RCUS compares with its peers on the latest reported figures
- RCUS's LTM Jun 2026 research & development of $497M is the highest of the 9 companies compared; the peer median is $307.11M.
- Its year-over-year change of +2.5% is the 8th highest of 9, against a peer median of +14.6%.
- Research & development amounts to 424.8% of revenue for RCUS, versus a peer median of 423.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $497M | +2.5% | +22.0% | 424.8% | |
| LTM Jun 2026 | $408.66M | +3.1% | +9.5% | 261.9% | |
| LTM Jun 2026 | $400.72M | -3.9% | +5.3% | 11118.8% | |
| LTM Mar 2026 | $342.68M | +13.3% | +6.1% | 518.8% | |
| LTM Jun 2026 | $324.68M | +6.6% | +49.8% | 456.5% | |
| LTM Jun 2026 | $289.55M | +15.9% | +30.4% | — | |
| LTM Sep 2026 | $252.23M | +33.2% | -5.7% | 138.2% | |
| LTM Mar 2026 | $220.45M | +47.2% | +54.5% | 423.6% | |
| LTM Jun 2026 | $55.75M | +34.8% | +26.4% | 12.4% | |
| Peer median (excluding RCUS) | $307.11M | +14.6% | +18.0% | 423.6% | |
Competitors are the stored peer set for RCUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 383M | 112M | 117M | 258M | 247M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 10M |
| Gross Profit | 383M | 112M | 117M | 258M | 237M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 96.0% |
| Research & Development | 257M | 288M | 340M | 448M | 523M |
| Selling, General & Admin | 72M | 104M | 117M | 120M | 110M |
| Operating Expenses | 329M | 392M | 457M | 588M | 623M |
| Depreciation & Amortization | 4M | 6M | 8M | 10M | 10M |
| EBITDA | 59M | (258M) | (291M) | (269M) | (335M) |
| EBITDA Margin | 15.4% | -230.4% | -248.7% | -104.3% | -135.6% |
| Operating Income | 54M | (280M) | (340M) | (330M) | (386M) |
| Operating Margin | 14.1% | -250.0% | -290.6% | -127.9% | -156.3% |
| Interest Income | 1M | 16M | 41M | 52M | 41M |
| Interest Expense | 0 | 2M | 2M | 4M | 8M |
| Other Income / Expenses | 1M | 14M | 39M | 47M | 33M |
| Income Before Tax | 55M | (266M) | (301M) | (283M) | (353M) |
| Pre-Tax Margin | 14.4% | -237.5% | -257.3% | -109.7% | -142.9% |
| Income Tax Expense | 2M | 1M | 6M | 1M | 0 |
| Net Income | 53M | (267M) | (307M) | (283M) | (353M) |
| Net Margin | 13.8% | -238.4% | -262.4% | -109.7% | -142.9% |
| EPS (Basic) | 0.76 | (3.71) | (4.15) | (3.14) | (3.29) |
| EPS (Diluted) | 0.71 | (3.71) | (4.15) | (3.14) | (3.29) |
| Weighted Avg Shares | 69.35M | 72M | 74M | 90.1M | 107.4M |
| Weighted Avg Shares (Diluted) | 73.97M | 72M | 74M | 90.1M | 107.4M |
Arcus Biosciences, Inc.
NYSE:RCUS
Intrinsic Alpha fair value
Locked
Current Price
$15.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.